Salud financiera de hoja de balance de GT Biopharma

Salud financiera controles de criterios 4/6

GT Biopharma tiene un patrimonio de los accionistas total de $5.5M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $9.3M y $3.8M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$9.25m
Patrimonio	US$5.51m
Total pasivo	US$3.76m
Activos totales	US$9.27m

Actualizaciones recientes sobre salud financiera

Recent updates

We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate

Jan 06

GT Biopharma files for $150M mixed shelf offering

Oct 13

We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully

Sep 21

GT Biopharma GAAP EPS of -$0.10 beats by $0.07

Aug 11

Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation

Jun 08

Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth

Nov 24

Getting To Know GT Biopharma

Jun 06

GT Biopharma names Gregory Berk Chief Medical Officer

Apr 26

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($9.3M) de GTBP superan a sus pasivos a corto plazo ($3.8M).

Pasivo a largo plazo: GTBP no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: GTBP está libre de deudas.

Reducción de la deuda: GTBP no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 135.9%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: GTBP tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: GTBP tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 10.1% cada año

Salud financiera de hoja de balance de GT Biopharma

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

GT Biopharma Announces 1 for 30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Nasdaq Listing Qualifications Department Determines the GT Biopharma's Eligibility for an Additional 180 Calendar Day Period, or Until February 20, 2024, to Regain Compliance

We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate

We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully

Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation

Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth

Recent updates

GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Announces CFO Changes

New major risk - Shareholder dilution

GT Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $3.219 million.

New major risk - Financial position

GT Biopharma, Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Share price stability

GT Biopharma Announces 1 for 30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nasdaq Listing Qualifications Department Determines the GT Biopharma's Eligibility for an Additional 180 Calendar Day Period, or Until February 20, 2024, to Regain Compliance

New major risk - Revenue and earnings growth

New major risk - Market cap size

GT Biopharma, Inc. Announces Board Changes

We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate

Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee

Price target decreased to US$4.00

High number of new and inexperienced directors

GT Biopharma files for $150M mixed shelf offering

We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully

Gt Biopharma, Inc. Affirms Manufacturing Timeline for Lead Investigational Asset GTB-3650

GT Biopharma GAAP EPS of -$0.10 beats by $0.07

GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Index

GT Biopharma, Inc. Appoints Alan L. Urban to Fill Vacant Seat on Board

Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation

GT Biopharma, Inc., Annual General Meeting, Jun 08, 2022

Price target decreased to US$17.33

High number of new and inexperienced directors

GT Biopharma, Inc. Announces CEO Changes

GT Biopharma, Inc Appoints Manu Ohri as Chief Financial Officer

Price target decreased to US$17.33

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021

Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth

Price target increased to US$25.33

High number of new and inexperienced directors

GT Biopharma Announces Updated Positive Safety Data from Phase 1 GTB-3550 Monotherapy Trike Trial an Investigational Immunotherapy for Refractory Cancers to Be Presented At ESMO Congress 2021

GT Biopharma, Inc. Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies

GT Biopharma, Inc. announced delayed 10-Q filing

GT Biopharma Provides Second Quarter 2021 Business Update

Price target increased to US$25.33

GT Biopharma Announces Interim GTB-3550 Trike Monotherapy Clinical Trial Results

Getting To Know GT Biopharma

GT Biopharma, Inc. Announces Update on the Commencement of the GTB-3550 Trike Monotherapy Phase 2 Clinical Trial and Solid Tumor Trike Product Candidates

GT Biopharma names Gregory Berk Chief Medical Officer

GT Biopharma, Inc. announced delayed annual 10-K filing

GT Biopharma, Inc. Updates Interim GTB-3550 Trike™ Clinical Trial Results

GT Biopharma, Inc. Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer

GT Biopharma, Inc. Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE, a Novel NK Cell Therapeutic Cancer Treatment

Gt Biopharma, Inc. Sign an Expanded GMP Manufacturing Agreement with Cytovance Biologics

GT Biopharma, Inc. has completed a Composite Units Offering in the amount of $23.65 million.

GT Biopharma, Inc. Announces Board Changes

GT Biopharma Announces Eighth Patient Begins Treatment of GTB-3550

GT Biopharma, Inc. Announces TriKE™ for the Treatment of Breast and GI Cancers

Gt Biopharma, Inc. and Cytovance Reaches Agreement for License Rights to Use Certain Bacterial and Mammalian Cell Lines and for GMP Manufacturing Services Performed to Date Regarding the Company's Trike™ Product Candidates

Dr. Greg Berk, M.D. Joins Board of Directors of GT Biopharma, Inc

GT Biopharma, Inc. Appoints Michael Handelman as Chief Financial Officer

GT Biopharma, Inc. Announces Advisory Board Appointments

GT Biopharma, Inc. announced that it has received $0.25 million in funding

GT Biopharma, Inc. announced that it has received $5.607 million in funding

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera